bioMérieux holds the majority of the market share for respiratory panel tests, and its market share is expected to increase, Lo added. bioMérieux’s, current BioFire FilmArray products grew 67% year-over-year due to exceptionally high sales of respiratory panels during the COVID-19 pandemic, including its pneumonia panel test, an indication commonly seen to develop in COVID-19 patients.
In addition to the pneumonia panel, bioMérieux’s current respiratory panel diagnostic test, while not yet testing for COVID-19, is a valuable diagnostic tool as it tests for 21 other common respiratory pathogens allowing either for a positive test result, indicating that the patient does not have COVID-19 but instead the common flu. On the other hand, should a patient test negative, the panel rules out the possibility of all other common respiratory infections. This diagnosis-by-deduction allows for informed-decision using an alternate testing method, and avoids burdening an already over-taxed COVID-19 testing system. This test is currently set to launch this year.